Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Prelude Therapeutics Incorporated (PRLD : NSDQ)

• Company Description    Prelude Therapeutics Incorporated is a clinical-stage precision oncology company. It is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorporated is based in Wilmington, United States. Number of Employees: 131

• Price / Volume Information    Yesterday's Closing Price: $2.90 Daily Weekly Monthly 20 Day Moving Average: 460,760 shares Shares Outstanding: 62.87 (millions) Market Capitalization: $182.31 (millions) Beta: 0.90 52 Week High: $3.00 52 Week Low: $0.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 88.31% 88.63% 12 Week 107.14% 103.80% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 175 Innovation Boulevard - Wilmington,DE 19805 USA ph: 302-467-1280 fax: - rdoody@preludetx.com http://www.preludetx.com

• General Corporate Information    Officers Krishna Vaddi - Chief Executive Officer and Director Paul A. Friedman - Chairman and Director Bryant Lim - Chief Financial Officer Martin Babler - Director Julian Baker - Director Peer Information Prelude Therapeutics Incorporated (GSAC) Prelude Therapeutics Incorporated (CASI) Prelude Therapeutics Incorporated (ALCD.) Prelude Therapeutics Incorporated (OMNN) Prelude Therapeutics Incorporated (CGPI.) Prelude Therapeutics Incorporated (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 74065P101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/09/26 Share - Related Items Shares Outstanding: 62.87 Most Recent Split Date: (:1) Beta: 0.90 Market Capitalization: $182.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.24 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.80 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 39.53% vs. Previous Quarter: 36.59% Sales Growth vs. Year Ago Period: 116.67% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -121.16 06/30/25 - -106.50 ROA 12/31/25 - - 09/30/25 - -84.93 06/30/25 - -79.07 Current Ratio 12/31/25 - - 09/30/25 - 3.21 06/30/25 - 3.68 Quick Ratio 12/31/25 - - 09/30/25 - 3.21 06/30/25 - 3.68 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -1,064.49 06/30/25 - -1,775.97 Book Value 12/31/25 - - 09/30/25 - 1.03 06/30/25 - 1.34 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©